Phathom Pharmaceuticals, Inc. (PHAT)
NASDAQ: PHAT · IEX Real-Time Price · USD
+0.35 (3.32%)
May 20, 2024, 4:00 PM EDT - Market closed

Company Description

Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases.

The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.

It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection.

The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals logo
Country United States
IPO Date Oct 25, 2019
Industry Biotechnology
Sector Healthcare
Employees 452
CEO Ms. Terrie J. Curran

Contact Details

100 Campus Drive, Suite 102
Florham Park, New Jersey 07932
United States
Phone (877) 742-8466

Stock Details

Ticker Symbol PHAT
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $19.00
CIK Code 0001783183
CUSIP Number 71722W107
ISIN Number US71722W1071
Employer ID 82-4151574
SIC Code 2834

Key Executives

Name Position
Terrie J. Curran President, Chief Executive Officer and Director
David A. Socks Co-Founder and Director
Dr. Azmi Nabulsi M.D., M.P.H. Co-Founder and Chief Operating Officer
Molly Henderson CPA, MBA Chief Financial and Business Officer
Dr. Aditya Kohli Ph.D. Co-Founder
Lawrence R. Miller Esq., J.D. General Counsel and Secretary
Tom Harris Chief Development Sciences Officer
Dr. Eckhard Leifke M.D., Ph.D. Chief Medical Officer
Martin J. Gilligan Chief Commercial Officer

Latest SEC Filings

Date Type Title
May 9, 2024 10-Q Quarterly Report
May 9, 2024 8-K Current Report
Apr 12, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 12, 2024 DEF 14A Other definitive proxy statements
Apr 12, 2024 ARS Filing
Apr 10, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Apr 1, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Mar 7, 2024 10-K Annual Report
Mar 7, 2024 8-K Current Report
Feb 13, 2024 8-K Current Report